Literature DB >> 11160699

Mucosal transmission and induction of simian AIDS by CCR5-specific simian/human immunodeficiency virus SHIV(SF162P3).

J M Harouse1, A Gettie, T Eshetu, R C Tan, R Bohm, J Blanchard, G Baskin, C Cheng-Mayer.   

Abstract

Nonhuman primate models are increasingly used in the screening of candidate AIDS vaccine and immunization strategies for advancement to large-scale human trials. The predictive value of such macaque studies is largely dependent upon the fidelity of the model system in mimicking human immunodeficiency virus (HIV) type 1 infection in terms of viral transmission, replication, and pathogenesis. Herein, we describe the efficient mucosal transmission of a CCR5-specific chimeric simian/human immunodeficiency virus, SHIV(SF162P3). Female rhesus macaques were infected with SHIV(SF162P3) after a single atraumatic application to the cervicovaginal mucosa. The disease course of SHIV(SF162P3)-infected monkeys is similar and as varied as natural HIV infection in terms of viral replication, gradual loss of CD4(+) peripheral blood mononuclear cells, and the development of simian AIDS-defining opportunistic infections. The SHIV(SF162P3)/macaque model should facilitate direct preclinical assessment of HIV vaccine strategies in addition to antiviral compounds directed towards envelope target cell interactions. Furthermore, this controlled model provides the setting to investigate immunologic responses and putative host-specific susceptibility factors that alter viral transmission and subsequent disease progression.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11160699      PMCID: PMC115146          DOI: 10.1128/JVI.75.4.1990-1995.2001

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  22 in total

1.  AIDS preclinical vaccine development: biennial survey of HIV, SIV, and SHIV challenge studies in vaccinated nonhuman primates.

Authors:  J T Warren; M A Levinson
Journal:  J Med Primatol       Date:  1999 Aug-Oct       Impact factor: 0.667

2.  Emerging cytopathic and antigenic simian immunodeficiency virus variants influence AIDS progression.

Authors:  J T Kimata; L Kuller; D B Anderson; P Dailey; J Overbaugh
Journal:  Nat Med       Date:  1999-05       Impact factor: 53.440

3.  Distinct pathogenic sequela in rhesus macaques infected with CCR5 or CXCR4 utilizing SHIVs.

Authors:  J M Harouse; A Gettie; R C Tan; J Blanchard; C Cheng-Mayer
Journal:  Science       Date:  1999-04-30       Impact factor: 47.728

4.  In vivo adaptation of SHIV(SF162): chimeric virus expressing a NSI, CCR5-specific envelope protein.

Authors:  R C Tan; J M Harouse; A Gettie; C Cheng-Mayer
Journal:  J Med Primatol       Date:  1999 Aug-Oct       Impact factor: 0.667

5.  Evolution of syncytium-inducing and non-syncytium-inducing biological virus clones in relation to replication kinetics during the course of human immunodeficiency virus type 1 infection.

Authors:  A B van 't Wout; H Blaak; L J Ran; M Brouwer; C Kuiken; H Schuitemaker
Journal:  J Virol       Date:  1998-06       Impact factor: 5.103

Review 6.  Mucosal transmission of simian immunodeficiency virus.

Authors:  C J Miller
Journal:  Curr Top Microbiol Immunol       Date:  1994       Impact factor: 4.291

7.  Selective transmission of human immunodeficiency virus type-1 variants from mothers to infants.

Authors:  S M Wolinsky; C M Wike; B T Korber; C Hutto; W P Parks; L L Rosenblum; K J Kunstman; M R Furtado; J L Muñoz
Journal:  Science       Date:  1992-02-28       Impact factor: 47.728

8.  Exclusive and persistent use of the entry coreceptor CXCR4 by human immunodeficiency virus type 1 from a subject homozygous for CCR5 delta32.

Authors:  N L Michael; J A Nelson; V N KewalRamani; G Chang; S J O'Brien; J R Mascola; B Volsky; M Louder; G C White; D R Littman; R Swanstrom; T R O'Brien
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

9.  Persistent infection of rhesus macaques with T-cell-line-tropic and macrophage-tropic clones of simian/human immunodeficiency viruses (SHIV).

Authors:  P A Luciw; E Pratt-Lowe; K E Shaw; J A Levy; C Cheng-Mayer
Journal:  Proc Natl Acad Sci U S A       Date:  1995-08-01       Impact factor: 11.205

10.  Vaccination with tat toxoid attenuates disease in simian/HIV-challenged macaques.

Authors:  C D Pauza; P Trivedi; M Wallace; T J Ruckwardt; H Le Buanec; W Lu; B Bizzini; A Burny; D Zagury; R C Gallo
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-28       Impact factor: 11.205

View more
  114 in total

1.  Active and selective transcytosis of cell-free human immunodeficiency virus through a tight polarized monolayer of human endometrial cells.

Authors:  H Hocini; P Becquart; H Bouhlal; N Chomont; P Ancuta; M D Kazatchkine; L Bélec
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

2.  Protection against rectal transmission of an emtricitabine-resistant simian/human immunodeficiency virus SHIV162p3M184V mutant by intermittent prophylaxis with Truvada.

Authors:  Mian-Er Cong; Ae S Youngpairoj; Qi Zheng; Wutyi Aung; James Mitchell; Elizabeth Sweeney; Debra L Hanson; R Michael Hendry; Charles Dobard; Walid Heneine; J Gerardo García-Lerma
Journal:  J Virol       Date:  2011-06-01       Impact factor: 5.103

3.  Durable protection from vaginal simian-human immunodeficiency virus infection in macaques by tenofovir gel and its relationship to drug levels in tissue.

Authors:  Charles Dobard; Sunita Sharma; Amy Martin; Chou-Pong Pau; Angela Holder; Zsuzsanna Kuklenyik; Jonathan Lipscomb; Debra L Hanson; James Smith; Francis J Novembre; J Gerardo García-Lerma; Walid Heneine
Journal:  J Virol       Date:  2011-11-09       Impact factor: 5.103

4.  Increased mucosal transmission but not enhanced pathogenicity of the CCR5-tropic, simian AIDS-inducing simian/human immunodeficiency virus SHIV(SF162P3) maps to envelope gp120.

Authors:  Mayla Hsu; Janet M Harouse; Agegnehu Gettie; Clarisa Buckner; James Blanchard; Cecilia Cheng-Mayer
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

5.  Addition of a single gp120 glycan confers increased binding to dendritic cell-specific ICAM-3-grabbing nonintegrin and neutralization escape to human immunodeficiency virus type 1.

Authors:  James Lue; Mayla Hsu; David Yang; Preston Marx; Zhiwei Chen; Cecilia Cheng-Mayer
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

6.  Rapid viral escape at an immunodominant simian-human immunodeficiency virus cytotoxic T-lymphocyte epitope exacts a dramatic fitness cost.

Authors:  Caroline S Fernandez; Ivan Stratov; Robert De Rose; Katrina Walsh; C Jane Dale; Miranda Z Smith; Michael B Agy; Shiu-Lok Hu; Kendall Krebs; David I Watkins; David H O'connor; Miles P Davenport; Stephen J Kent
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

7.  Evidence for persistent, occult infection in neonatal macaques following perinatal transmission of simian-human immunodeficiency virus SF162P3.

Authors:  Pushpa Jayaraman; Tuofu Zhu; Lynda Misher; Deepika Mohan; LaRene Kuller; Patricia Polacino; Barbra A Richardson; Helle Bielefeldt-Ohmann; David Anderson; Shiu-Lok Hu; Nancy L Haigwood
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

8.  Control of viremia and maintenance of intestinal CD4(+) memory T cells in SHIV(162P3) infected macaques after pathogenic SIV(MAC251) challenge.

Authors:  Bapi Pahar; Andrew A Lackner; Michael Piatak; Jeffrey D Lifson; Xiaolei Wang; Arpita Das; Binhua Ling; David C Montefiori; Ronald S Veazey
Journal:  Virology       Date:  2009-03-18       Impact factor: 3.616

9.  Efficient mucosal transmissibility but limited pathogenicity of R5 SHIV SF162P3N in Chinese-origin rhesus macaques.

Authors:  Alexandra Mumbauer; Agegenhu Gettie; James Blanchard; Cecilia Cheng-Mayer
Journal:  J Acquir Immune Defic Syndr       Date:  2013-04-15       Impact factor: 3.731

10.  Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C.

Authors:  James M Binley; Elizabeth A Lybarger; Emma T Crooks; Michael S Seaman; Elin Gray; Katie L Davis; Julie M Decker; Diane Wycuff; Linda Harris; Natalie Hawkins; Blake Wood; Cory Nathe; Douglas Richman; Georgia D Tomaras; Frederic Bibollet-Ruche; James E Robinson; Lynn Morris; George M Shaw; David C Montefiori; John R Mascola
Journal:  J Virol       Date:  2008-09-24       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.